Professor Gerard Evan, FRS

Scientific Advisory Board Member
Gerard Evan

Professor Evan’s research focuses on the molecular basis of cancer. To address this problem, he has developed a novel class of genetically engineered mouse in which individual oncogenes and/or tumour suppressor genes may be systemically toggled off and on, reversibly and at will, in vivo. In this way the most effective therapeutic targets can be identified. Using two such mouse models, his research has directly ascertained the therapeutic impact, efficacy and side effects of Myc inhibition and p53 restoration – two key targets involved in the process of cancer cell replication and regulation - establishing both mechanism of action and therapeutic index.

Professor Evan serves as Member of the Scientific Advisory Board at Ensemble Discovery Corporation, is a Gerson and Barbara Bass Baker Distinguished Professor of Cancer Biology at the University of California San Francisco, Co-leader of the Cell Cycling and Signaling Program at the UCSF Comprehensive Cancer Center, which he helped create in 1999 and is Head of the Department of Biochemistry at the University of Cambridge. 

Gerard Evan received his BA in Biochemistry from the University of Oxford (St. Peter’s College) in 1977 and his PhD in Molecular Immunology in 1981 from the University of Cambridge (King’s College). He worked in the laboratory of J. Michael Bishop at UCSF from 1982-84 and then returned to the UK to become an Assistant Member of the Cambridge Branch of the Ludwig Institute for Cancer Research and a Research Fellow of Downing College, Cambridge. In 1988 he joined the Imperial Cancer Research Fund (ICRF) Laboratories in London as a Senior Scientist (1988-90) and then Principal Scientist (1990-1999). He was awarded the Pfizer prize in Biology in 1995, and in 1996 was elected as the Royal Society’s Napier Professor of Cancer Research. In 1999 he was elected a Fellow of the UK Academy of Medical Sciences and later that year appointed to the Gerson and Barbara Bass Baker Distinguished Professor of Cancer Biology at the University of California, San Francisco. He was elected to the Royal Society in 2004, to the Neal Levitan Research Chair of the Brain Tumor Society and, in 2006, became a Senior Scholar of the Ellison Medical Research Foundation for Aging. In 2009, he was elected to the Sir William Dunn Chair of Biochemistry in the University of Cambridge where he is now Head of the Department of Biochemistry.